Polymer-based drug delivery for targeted GI tract release (stomach, intestine, colon). Patents | 26 February 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Patent Details Related patent documents CA3060026 EP3612196 WO/2018/193337 US20200129442 US20230181479 Granted US and Indian Patent Actorius Innovations and Research View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

PD-L1 on CTCs and ctDNA enables real-time monitoring of breast cancer progression. Publications | 3 June 2025 PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Background Tumor-derived components, such as dual biomarkers including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), provide comprehensive real-time insights into the tumor microenvironment. Minimal cellular residual disease (MCRD), dynamic cell surface protein overexpression, residual tumor burden after curative-intent resection, and decisions regarding adjunct therapy or therapy de-escalation are critical aspects of patient management. Similar to the PD-L1 combined positive score (CPS) in tissue samples, PD-L1 expression on CTCs represents a promising dynamic biomarker, particularly in the context of epithelial-to-mesenchymal transition (EMT). EMT may contribute to immune evasion by deactivating T cells, thereby facilitating micro-metastatic progression, which remains challenging to detect and manage. In this study, we report PD-L1 expression as a dynamic biomarker on circulating tumor cells across early- to late-stage breast cancer patients. Methods In this retrospective analysis, peripheral blood samples from 1,294 breast cancer patients were evaluated for the presence of CTCs, PD-L1 expression on CTCs, and CTC clusters. CTCs were enumerated using the OncoDiscover platform, approved by CDSCO-India, from 1.5 mL of peripheral blood. The system consists of a multi-component magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were identified based on EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ markers. PD-L1 expression on CTCs was quantified using linear intensity gradients of fluorescence signals acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate mean CTC distribution, perform regression analysis, and assess CTC predictability. Results CTC counts ranged from 1 to 20 per 1.5 mL of blood. At baseline analysis, 73.20% (n = 978) of patients had ≥1 CTC. Among patients with detectable CTCs, 87.69% (n = 406 of 463) exhibited PD-L1 expression. The highest proportion of total CTCs (~21.61%, n = 1,125) was observed in the 41–50-year age group. The highest frequency of CTC clusters (~29.08%, n = 41) and PD-L1–positive CTCs (~42.91%, n = 324) was observed in the 51–60-year age group. CTC clusters were detected in 2.71% (n = 141) of total patients. The mean CTC count (including clusters) was 3.90, while the mean PD-L1–positive CTC count was 3.40. The computational model demonstrated a correlation between blood-based outcomes and normal probability scores. Conclusions The observed inter-patient heterogeneity suggests potential biological and pharmacodynamic relevance of both CTCs and PD-L1 expression. Larger clinical studies are warranted to further evaluate PD-L1 expression on CTCs, particularly in early-stage cancers. Patients with minimal cellular residual disease, despite the absence of radiographic evidence, may represent a higher-risk group for metastasis progression and may benefit from enhanced stratification strategies. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Expert Insight | 28 August 2022 Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Cancer relapse and metastasis are responsible for the vast majority of cancer-related fatalities, often because traditional imaging tools like CT and MRI scans fail to catch the disease's return in time. This video highlights a groundbreaking and highly affordable blood test—India's first-in-class medical device approved by the Drug Controller General of India. Developed by Dr. Jayant Khandare, the OncoDiscover test requires only a small volume of blood to identify circulating tumor cells (CTCs) and detect minimal residual disease before it becomes uncontrollable. Clinically validated in partnership with Tata Memorial Hospital in Mumbai, this painless innovation provides oncologists with a powerful tool to monitor patients, optimize treatment, and ensure families never have to hear the dreaded words, "It's too late." Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 analysis helps detect MRD and guide therapy in colorectal cancer. Publications | 3 June 2024 ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Background In stage III colorectal cancer (CRC) patients, the extent of oxaliplatin-based adjuvant therapy remains uncertain. Approximately 25–50% of stage II–III CRC patients develop recurrence and metastasis even after comprehensive treatment, largely attributed to occult disease and minimal residual disease (MRD). Circulating tumor cells (CTCs) represent a bio-mechanistic source of extravasation leading to micro-metastatic disease. CRC patients receiving reduced adjuvant therapy (3–6 months) are known to exhibit increased CTC counts and positivity rates due to the emergence of resistant clones. Assays that detect CTCs and the expression of programmed death-ligand 1 (PD-L1) as a dynamic biomarker simultaneously have significant clinical implications, particularly when tissue biopsy samples are inadequate to identify molecular targets for immune checkpoint inhibitor (ICI) therapy. Methods In a retrospective study, 182 CRC patients were analyzed for the presence and distribution of CTCs at baseline and across follow-ups (0–4 follow-ups). Peripheral blood (1.5 ml) samples were analyzed using the CDSCO-approved OncoDiscover platform, which consists of a multifunctional magneto-nanosystem mediated by anti-epithelial cellular adhesion molecule (EpCAM) antibodies. CTCs were evaluated in patients with early-stage disease (pre- and post-treatment), progressive disease, disease-free status (DFS), and metastasis. Isolated cells were immunostained to detect CK18+, CD45-, DAPI+, and PD-L1+ expression. PD-L1 expression on CTCs was validated by analyzing the linear intensity gradients of fluorescence signals. CTCs were classified as PD-L1 negative when weak or no fluorescence signal was detected and PD-L1 positive when strong fluorescence signals were observed using automated image acquisition on a Zeiss fluorescence microscope. Results Among the cohort of 182 CRC patient samples, 128 (70.3%) showed the presence of CTCs. A fluorescence intensity-based assay was developed to evaluate PD-L1 expression as a robust functional biomarker for molecular characterization of CTCs. The distribution of CTCs ranged from 1 to 9 cells. The mean fluorescence intensity value and cut-off for PD-L1 expression in CTCs was approximately 1.02. Notably, 54 patients (42.2%) with CTCs showed positive PD-L1 expression. CTC-positive patients with PD-L1 expression were observed across all stages, including early-stage disease, progressive disease, and metastasis. Patients without detectable CTCs (n = 54, 29.7%) either had clinically stable disease or were in DFS with no radiographic evidence of disease. Conclusions PD-L1 overexpression on CTCs represents a dynamic blood-based biomarker indicating disease progression even in patients with DFS status. Enumeration of CTCs along with assessment of PD-L1 expression may enable more individualized treatment strategies for CRC patients and support better monitoring of disease progression and therapeutic response. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius ISLB 2025 | 1-3 November 2025 Events | 3 November 2025 ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Some glimpses from ISLB 2025 Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

N-Cadherin CTC capture identifies EMT-CTCs linked to metastasis and treatment resistance. Publications | 30 August 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Introduction: Epithelial-to-mesenchymal transition (EMT) enables tumour cells to lose epithelial characteristics, acquire enhanced motility and aggressive invasiveness, and activate metastatic dissemination. Circulating tumour cells (CTCs) undergoing true EMT possess greater metastatic potential than purely epithelial CTCs because they exhibit increased survival in the bloodstream, immune evasion, and the ability to colonise distant organs. Thus, detection and characterization of EMT-CTCs provide clinically valuable insights into metastatic risk, disease progression, and treatment resistance beyond conventional epithelial CTC enumeration. Here, we report an N-Cadherin affinity-based ligand CTC-capture platform for capturing CTCs demonstrating varied EMT-CTC phenotypes. Methods: Retrospectively, we analyzed blood samples from 30 cancer patients, including colorectal cancer stages I–IV (n=9), breast/TNBC (n=7), advanced lung adenocarcinoma (n=2), pancreatic cancer, anaplastic thyroid cancer, endometrial cancer, head and neck cancer, melanoma, and others. The cohort comprised 18 female and 12 male patients aged 19–84 years. We first validated Vimentin-positive MCF-7 cells using the OncoMetastat platform containing N-Cadherin glass beads for cellular localization. CTCs were captured using N-Cadherin glass beads from 1.5 mL of blood and subsequently confirmed based on Vimentin+, DAPI+, N-Cadherin+, and CD45− expression using a Nikon Ti-2 fluorescence microscope. Results: Vimentin-positive CTCs were detected in 27/30 (90%) cancer patient blood samples. A total of 42 CTCs were captured, with a mean distribution of approximately 1.4 CTCs per sample and a range of 1–3 CTCs. Among the isolated CTCs, 13/42 (30.9%) expressed cellular N-Cadherin. Importantly, N-Cadherin expression was observed in 5/10 (50%) colorectal cancer (CRC) samples and 3/7 (42.8%) breast cancer samples. In six patients, intra-CTC heterogeneity was observed, with both N-Cadherin-positive and N-Cadherin-negative CTCs. The MCF-7 cell study demonstrated >90% cell capture using the N-Cadherin affinity platform, with Vimentin localization. Conclusion: We demonstrate the capture of true epithelial-to-mesenchymal transitioning CTCs using an affinity-based N-Cadherin system in cancer patients. Further studies are required to investigate comparative CTC detection using anti-EpCAM antibodies and N-Cadherin, as well as their association with clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Research Scientist Publication Date: 26 Aug 2026 | Last Application Date: 6 Oct 2026 Apply Now Department Research & Development Location Pune, India Experience 3–5 years Role Overview The Research Scientist will contribute to Actorius' research and development programs in biotechnology, cancer diagnostics, circulating tumor cells and related scientific areas. The role will involve experimental research, data analysis, scientific documentation and collaboration with multidisciplinary R&D teams. Key Responsibilities Plan and execute laboratory experiments according to defined research objectives and protocols. Conduct research related to CTCs, cancer biology, liquid biopsy, molecular biology and related areas. Perform laboratory experiments, sample processing and analytical procedures. Analyze, interpret and document experimental results. Maintain accurate laboratory records, research data and documentation. Support development, optimization and validation of laboratory methods and processes. Conduct literature reviews and remain updated on relevant scientific developments. Prepare technical reports, research summaries, presentations and scientific documentation. Contribute to research publications, abstracts, presentations and intellectual-property activities where applicable. Collaborate with scientific, clinical, product and technical teams. Follow laboratory safety, quality and documentation standards. Identify experimental challenges and propose scientifically sound solutions. Support technology development and continuous improvement initiatives. Qualifications & Skills Master's or PhD in Biotechnology, Life Sciences, Biochemistry, Molecular Biology, Microbiology, Biomedical Sciences or a related discipline. 3–5 years of relevant research experience in biotechnology, cancer biology, molecular biology, diagnostics, CTC research, liquid biopsy or a related field. Strong laboratory and experimental skills. Experience with relevant analytical and molecular biology techniques is preferred. Strong scientific writing, data interpretation and documentation skills. Ability to work independently as well as within multidisciplinary teams. Strong analytical thinking, attention to detail and problem-solving abilities. What We Look For At Actorius, we value people who combine ownership, curiosity, scientific thinking and execution . We look for professionals who are: Passionate about healthcare and meaningful innovation. Comfortable working in a fast-growing, innovation-driven environment. Curious and willing to learn. Strong in communication and collaboration. Focused on outcomes and accountability. Comfortable working across functions. Ethical and professional in their approach. Motivated by the opportunity to contribute to technologies that can impact cancer care. About Actorius Actorius Innovations & Research Pvt. Ltd. is an innovation-driven biotechnology and medical diagnostics company focused on developing technologies that address critical challenges in cancer care. From breakthrough research to clinically meaningful diagnostics, Actorius works at the intersection of biotechnology, biomaterials, circulating tumor cells (CTCs), liquid biopsy and oncology diagnostics . Our goal is to translate deep scientific understanding into practical technologies that can help clinicians make more informed decisions and improve patient outcomes. Our flagship OncoDiscover® CTC Test is India's first DCGI/CDSCO-approved blood test for detecting circulating tumor cells and supporting cancer monitoring. Actorius also continues to develop advanced technologies such as OncoMetastat® , alongside its broader research and diagnostic platforms. We are looking for dynamic thinkers, problem-solvers and doers who want to work on meaningful challenges in healthcare and contribute to technologies that can make a difference in cancer care. Why Join Actorius? Work on Meaningful Healthcare Challenges Contribute to technologies focused on cancer diagnostics, CTCs, liquid biopsy and oncology. Be Part of an Innovation-Driven Organisation Work alongside scientists, clinicians, business leaders and healthcare professionals. Learn Across Disciplines Actorius encourages interdisciplinary thinking across science, technology, diagnostics, marketing, sales and operations. Build With Purpose Our work is driven by the belief that better biological insights can contribute to better healthcare decisions. Grow With the Organisation Join a growing team where ownership, initiative and individual contribution matter. How to Apply Click the below link to apply. Candidates are encouraged to clearly mention the position and preferred location in their application. Apply Now

CTCs and PD-L1 profiling support MRD detection and therapy decisions in ovarian cancer. Publications | 3 June 2024 ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Background In the precision oncology era, monitoring treatment response using circulating blood-based biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) is rapidly being evaluated and established. The leading cause of mortality in ovarian cancer patients is delayed diagnosis and the inability to effectively select patients for targeted therapies, including immune checkpoint blockade (ICB) agents. Treatment for ovarian cancer usually involves a combination of surgery and chemotherapy. However, postoperative resection and therapy with curative intent often fail to account for minimal cellular disease (MCD). The dissemination of circulating tumor cells (CTCs) represents minimal residual disease (MRD), which may diffuse and cause micro-metastasis through epithelial-to-mesenchymal transition (EMT) and bio-mechanistic activation in blood circulation. Simultaneous detection of overexpression of programmed death-ligand 1 (PD-L1) on CTCs as a dynamic biomarker may be useful for assessing patients for immune checkpoint inhibitor (ICI) therapy. Methods In a retrospective analysis of real-world data, peripheral blood samples from 75 ovarian cancer patients were analyzed for the presence of CTCs, with and without PD-L1 expression, and for the presence of CTC clusters. CTCs were detected using the CDSCO-approved OncoDiscover platform from 1.5 ml of peripheral blood. The platform is a multifunctional magneto-nanosystem mediated by anti-epithelial cellular adhesion molecule (EpCAM) antibodies. CTCs were identified as positive when EpCAM+, CK+, PD-L1+, DAPI+, and CD45- markers were present. PD-L1 expression on CTCs was analyzed based on the linear intensity gradients of fluorescence signals using image acquisition on an automated Zeiss microscope. Results Baseline sample analysis showed that 86% (n = 65) of patients had at least one CTC per 1.5 ml of blood. The CTC distribution ranged from 1 to 9 CTCs. Among the patients with CTCs, 46.15% (n = 30) showed PD-L1 expression. Notably, the highest number of CTCs (~26.7%, n = 23) was observed in the 41–50 age group. Additionally, 8% (n = 6) of the total patients showed the presence of CTC clusters. The presence of CTCs with PD-L1 expression and CTC clusters did not show a correlation with factors such as staging, follow-ups, metastasis, or disease-free survival (DFS) status. Conclusions We observed the presence of minimal cellular disease (MCD) and minimal residual disease (MRD) in ovarian cancer patients despite treatment with curative intent. Detection of CTCs, CTC clusters, and PD-L1 overexpression as real-time dynamic biomarkers may help assess early metastasis, disease progression, and regression. These biomarkers may also support the selection of patients suitable for immune checkpoint inhibitor (ICI) therapy when tissue samples are inadequate or unavailable, potentially improving clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Publications | 27 January 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Simple summary Circulating tumor cells (CTCs), which are cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate. Unlike static tissue samples, CTCs allow repeated assessments that track tumor evolution, therapeutic response, and minimal residual disease. Hence, CTCs offer a minimally invasive, real-time alternative to tissue biopsies for cancer monitoring, particularly through surface protein biomarkers like PD-L1, HER2, and EGFR. As detection technologies improve and the clinical relevance of CTCs continues to be established, CTC profiling is poised to significantly influence the future of precision oncology. Abstract Circulating tumor cells (CTCs) are shed from the primary tumor into the bloodstream and represent dynamic molecular biomarkers for monitoring the progression of cancer. While profiling tumor tissues with overexpression of cell surface markers, such as PD-L1 or HER2, is standard in guiding therapy, tissue samples are often inaccessible and inadequate, especially post-surgery or in cases of recurrence. Emerging clinical evidence indicates that CTC counts and biomarker surface expression can predict prognosis and therapeutic resistance more accurately than imaging or tissue-based approaches. Recent advancements in CTC detection methods, based on physical properties or surface markers (e.g., EpCAM), coupled with next-generation sequencing (NGS), have enabled the isolation of these rare cells and their molecular characterization. Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations AACR 2026 Publications Publications | 17 March 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Abstract Background While 90% of cancer deaths are associated with metastasis, it is imperative to monitor early-stage cancer patients for the presence of systemic disease to improve overall survival (OS) and progression-free survival (PFS). Despite complete remission, up to 25–50% of colorectal cancer (CRC) stage II–III and early breast cancer cases are known to relapse. Furthermore, the existence of microtumors often remains undetected by radio-imaging tools due to their limited detection thresholds. Following curative-intent therapies, minimal residual cellular disease (MRCD) may persist and is often represented by circulating tumour cells (CTCs). These cells are known for their ability to extravasate and invade distant sites from the primary tumor. They can also evade immune surveillance. Therefore, there is a need to design safer extracorporeal devices for the capture and depletion of CTCs, particularly those overexpressing PD-L1. In this study, we designed an automated device to capture and remove CTCs from whole blood. Methods We developed an automated microprocessor-operated fluidic device, OncoMetastat, equipped with cartridges for blood and reagent tubes, along with a 3D-printed biocompatible spiral channel. The controller unit powers peristaltic pumps that circulate blood through the spiral channel (96 mm diameter × 6 mm height). The system incorporates 2 mm glass beads conjugated with antibodies and transferrin. Additionally, four vibrators provide micro-stirring to enhance CTC capture from 5–10 mL of patient blood samples (n = 54). White blood cell (WBC) count, hemolysis, and protein binding were measured. The beads were scanned for CTCs using markers CK18⁺, DAPI⁺, and CD45⁻ through an automated imaging system and compared with the OncoDiscover CTC enumeration platform approved by CDSCO India. We analyzed true positives, false negatives, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Results Retrospectively, blood samples from 54 pan-cancer patients—including breast, colorectal, prostate, and lung cancer—were analyzed to capture and deplete CTCs. The OncoMetastat platform demonstrated a capture efficiency of over 90% when compared with the OncoDiscover platform. Automated scanning achieved 100% efficiency in CTC imaging compared with manual imaging. Leukocyte adhesion was low with anti-EpCAM and transferrin-coated glass beads (2 ± 1 WBCs per sample, n = 54). WBC counts showed cancer-type-specific trends (mean WBC count/mL: 4.9 × 10⁶ for breast cancer, 3.9 × 10⁶ for rectal cancer, and 3.5 × 10⁶ for prostate cancer), representing a 40% decrease compared with healthy controls (mean 6.9 × 10⁶ WBCs/mL). Clinically insignificant hemolysis (<1%) and minimal protein binding (~1.5%) were observed. Vibration-assisted operation enhanced CTC sequestration, achieving more than 90% cell capture efficiency. The platform demonstrated sensitivity of 94.4%, specificity of 92.9%, PPV of 94.4%, NPV of 92.9%, and overall accuracy of 93.8% for CTC capture. Conclusion This study demonstrates efficient and specific depletion of CTCs using the automated device. The platform shows potential as an extracorporeal system capable of removing CTCs from whole blood, thereby offering a promising strategy to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover: affordable, rapid CTC platform for HNC patients in developing nations. Publications | 4 June 2019 ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Background Liquid biopsy technologies are often unaffordable and unavailable in developing countries, despite these regions having the highest cancer burden and mortality rates. Current circulating tumor cell (CTC) technologies face significant clinical concerns, including non-specificity, low efficiency, high blood volume requirements, long turnaround times, and exorbitant costs (~$900–$1,400). We report an extremely low-cost, innovative nanosystem for the rapid enumeration of CTCs with higher specificity and efficiency. Methods We designed a nanosystem mediated by the conjugation of anti-EpCAM through a multi-reactive glutathione spacer, a carbon allotrope, and an amine-terminated dendrimer. The platform was evaluated for enhanced aqueous dispersibility and increased interaction with CTCs for rapid isolation and enumeration in 100 head and neck cancer (HNC) patients. These patients had various primary tumor sub-sites, including the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, salivary gland, and thyroid. The captured cells were immunostained, and the optimal fluorescence acquisition intensity was validated by accounting for CTCs with CK18 protein expression. Our method achieved the complete elimination of false-positive normal cell (NC) counts. The analysis was performed using only 1.5 ml of collected blood samples. Results The CTC distribution in the cohort study ranged from 1 to 85 cells per 1.5 ml of blood. In more than 80% of patients' CTCs, the quantitative estimation of anti-CK18 protein overexpression indicated an intensity approximately 10-fold higher than that of normal cells. Compared to treatment-naive, recurrent, and disease-free patients, the spread of CTC numbers across the clinical range appeared to be tight (close to the mean value). The CTC enumeration sensitivity linearity was ~99.2%, and the complete enumeration process time was under 3 hours per 1.5 ml of blood. Consequently, an efficient, rapid, and affordable CTC platform was designed and clinically validated. Conclusions The "OncoDiscover" liquid biopsy technology for CTC enumeration is poised to revolutionize the field due to its high sensitivity and affordability (~$120). It addresses a major unmet medical need in the developing world. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | Press Release Press Release | 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story You can also read in Lokmat times , ANI News and Business Standard Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe